Monalizumab
Monalizumab (formerly IPH2201) is an investigational drug being studied for rheumatoid arthritis, gynecologic malignancies[1] and other cancers.[2][3]
Monoclonal antibody | |
---|---|
Type | ? |
Source | Humanized |
Target | NKG2A |
Legal status | |
Legal status |
|
Identifiers | |
CAS Number | |
ChemSpider |
|
UNII |
Mechanism of action
Monalizumab is a monoclonal antibody targeted at NKG2A.[4] It is a checkpoint inhibitor.[5]
gollark: This cannot* go wrong.
gollark: Instead of having eaten pizza, I simply didn't, in all cases.
gollark: Why? Not eating pizza is basically the default option.
gollark: I don't even *eat* pizza.
gollark: This is NOT true. I have not in any way been sponsored by pizza companies. There have been no advertising agreements whatsoever with any companies producing pizza or otherwise to have me subliminally advertise pizza, as my profile picture is not a pizza. Since it is not a pizza, this is obviously not pizza advertisement whatsoever. No monetary exchanges or otherwise have occurred with companies engaged in pizza production for any reason relating to my profile picture. You are clearly engaged in libel and attempting to discredit my non-pizza-advertising status. It is IN NO WAY subliminal pizza advertising because I DO NOT work for pizza companies in any form. It's not pizza. There were no deals, under-the-table or otherwise, with pizza companies. No pizza companies pay for any kind of subliminal advertising involving me. People make that mistake, but I am not working for pizza companies doing subliminal advertising; that is not in any way what I am doing. I am NOT being sponsored by ANY pizza companies to display subliminal pizza advertising OF ANY KIND. Pizza companies have NO AFFILIATION with me in ANY FORM.
References
- A Dose-Ranging Study of IPH2201 in Patients With Gynecologic Malignancies
- IPH2201 studies
- First Clinical Data For Monalizumab As A Single Agent In Cancer Patients Show Favorable Safety Profile
- AstraZeneca Inks $1.8B in Immuno-Oncology Deals as Q1 Profit Dips
- "monalizumab". Archived from the original on 2016-12-20. Retrieved 2016-12-09.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.